Peter Hansen Hims & Hers ( NYSE: HIMS ), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's ( LLY ) GLP-1 tirzepatide was no longer in shortage. The update is the.
Back to Health Page
